IBI 3003
Alternative Names: IBI-3003Latest Information Update: 16 Jun 2024
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 12 Jun 2024 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in Australia (Parenteral) (Innovent Biologics pipeline, June 2024)
- 18 Oct 2023 Innovent Biologics plans a first-in-human phase I/II trial in Multiple myeloma (Second line therapy or greater) in Australia (Parenteral) in February 2024 (NCT06083207)
- 18 Oct 2023 IBI 3003 is available for licensing as of 18 Oct 2023. https://www.innoventbio.com/Collaborations/PartnerOfChoice#PartnerOfChoice